clinical trial · NCT04342910
Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
Jiangsu HengRui Medicine Co., Ltd.·phase3·recruiting·n = 550
Gastric CancercamrelizumabApatinib MesylatePaclitaxelIrinotecan
brief summary
This is a study for participants with advanced gastric or gastroesophageal junction adenocarcinoma who have had tumor progression after first-line platinum-contained therapy. The primary study hypotheses are that camrelizumab (SHR-1210) combined with apatinib prolongs overall survival (OS) for participants with tumors that show positive programmed cell death ligand 1 (PD-L1) expression.
started
Sep 21, 2020
primary completion
Apr 1, 2026
completion
Sep 1, 2026
last updated
Jan 20, 2026
official title
A Study of Camrelizumab (SHR-1210) Combined With Apatinib Versus Paclitaxel or Irinotecan in Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma Progressed After First-line Chemotherapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol